Introducing in vivo pancreatic cancer models for the study of new therapeutic regimens

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F22%3A00014158" target="_blank" >RIV/75010330:_____/22:00014158 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/22:10453598 RIV/00064173:_____/22:43925036 RIV/00216208:11120/22:43925036

Result on the web

<a href="https://www.prolekare.cz/casopisy/rozhledy-v-chirurgii/2022-12-1/zavedeni-in-vivo-modelu-karcinomu-pankreatu-pro-studium-novych-terapeutickych-rezimu-133432?hl=en" target="_blank" >https://www.prolekare.cz/casopisy/rozhledy-v-chirurgii/2022-12-1/zavedeni-in-vivo-modelu-karcinomu-pankreatu-pro-studium-novych-terapeutickych-rezimu-133432?hl=en</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.33699/PIS.2022.101.12.584-592" target="_blank" >10.33699/PIS.2022.101.12.584-592</a>

Result language

angličtina

Original language name

Introducing in vivo pancreatic cancer models for the study of new therapeutic regimens

Original language description

Introduction: Pancreatic cancer is a severe oncological disease with an ever-increasing incidence and a high rate of morbidity and mortality. Therapeutic options are limited and the five-year overall survival rate is 7–20%, depending on the possibility of surgical resection and the earliness of detection. Most patients with this diagnosis die due to the resistance of tumour cells and their microenvironment to the used treatment regimes. Methods: In our study, we focused on the implementation of two in vivo models, which are the cell-line derived xenograft (CDX) and the patient-derived xenograft (PDX). These two models differ significantly from each other methodologically, technically, financially, but also in their achieved results. Results: In a pilot study, we managed to successfully implement the CDX model with a very aggressive and resistant PaCa-44 line of pancreatic cancer in a total of 30 NU/NU strain mice. Furthermore, we created three PDX models with various subtypes of pancreatic cancer from patients operated at the University Hospital Kralovske Vinohrady, Department of General Surgery. These tumours were re-transplanted into subsequent generations of 23 individuals of NOD/SCID strain and 47 NU/NU strain mice. The established CDX and PDX models are then used to compare conventional and experimental chemotherapy regimens. Conclusion: The next steps will be to evaluate the effects of treatment regimens by using imaging and molecular genetic methods and to optimise the entire process for further use in precise personalised medicine for patients with pancreatic cancer. The upcoming goal is to create a library of PDX models of the most common pancreatic ductal adenocarcinoma and other rare subtypes of pancreatic cancer.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

10608 - Biochemistry and molecular biology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Rozhledy v chirurgii

ISSN

0035-9351

e-ISSN

—

Volume of the periodical

101

Issue of the periodical within the volume

12

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

9

Pages from-to

584-592

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85147791071